Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma

Kelly J. Butnor, Andrew G. Nicholson, D. Craig Allred, Dani S. Zander, Douglas W. Henderson, Roberto Barrios, Abida K. Haque, Timothy C. Allen, Deanna E. Killen, Philip T. Cagle

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Context.-Metastatic renal cell carcinoma (MRCC) involving the thorax can be difficult to distinguish from diffuse malignant mesothelioma (DMM) using traditional morphologic approaches. Standard panels of immunohistochemical markers are of limited benefit. Objective.-To investigate several antibodies to renal cell carcinoma-associated proteins for differentiating MRCC from DMM. Design.-One hundred DMMs and 20 MRCCs were evaluated for immunoexpression of erythropoietin. The same cases and an additional 45 DMMs were evaluated for CD10 and renal cell carcinoma marker (RCCMa) immunoreactivity. Results.- Erythropoietin was expressed in 100% of DMMs and MRCCs. Staining for CD10 was observed in 54% of DMMs and 100% of MRCCs. RCCMa stained 26% of DMMs and 55% of MRCCs. Although erythropoietin staining was similarly strong and diffuse in both DMM and MRC, patterns of staining for RCCMa and CD10 differed between MRCC and DMM. Immunoreactivity was strong and diffuse for both RCCMa and CD10 in most MRCCs. Of CD10-positive DMMs, nearly half showed staining in less than 50% of tumor cells and about one fourth of positive cases exhibited only weak to moderately intense staining. Only half of RCCMa-positive DMMs showed staining in more than 49% of tumor cells and staining was only weak to moderately intense in most cases. Conclusions.-Given the overlap in the expression of renal cell carcinoma markers in MRCC and DMM, results with these markers must be interpreted cautiously and should be used in conjunction with mesothelium-associated markers. Differences in expression may potentially help distinguish MRCC from DMM inasmuch as strong and diffuse expression of RCCMa and CD10 supports a diagnosis of MRCC over DMM.

Original languageEnglish (US)
Pages (from-to)823-827
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Volume130
Issue number6
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Erythropoietin
Renal Cell Carcinoma
Staining and Labeling
Malignant Mesothelioma
Neoplasms
Thorax
Epithelium

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. / Butnor, Kelly J.; Nicholson, Andrew G.; Allred, D. Craig; Zander, Dani S.; Henderson, Douglas W.; Barrios, Roberto; Haque, Abida K.; Allen, Timothy C.; Killen, Deanna E.; Cagle, Philip T.

In: Archives of Pathology and Laboratory Medicine, Vol. 130, No. 6, 06.2006, p. 823-827.

Research output: Contribution to journalArticle

Butnor, KJ, Nicholson, AG, Allred, DC, Zander, DS, Henderson, DW, Barrios, R, Haque, AK, Allen, TC, Killen, DE & Cagle, PT 2006, 'Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma', Archives of Pathology and Laboratory Medicine, vol. 130, no. 6, pp. 823-827.
Butnor, Kelly J. ; Nicholson, Andrew G. ; Allred, D. Craig ; Zander, Dani S. ; Henderson, Douglas W. ; Barrios, Roberto ; Haque, Abida K. ; Allen, Timothy C. ; Killen, Deanna E. ; Cagle, Philip T. / Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. In: Archives of Pathology and Laboratory Medicine. 2006 ; Vol. 130, No. 6. pp. 823-827.
@article{6be666c44cd0438194ce765b15ef528e,
title = "Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma",
abstract = "Context.-Metastatic renal cell carcinoma (MRCC) involving the thorax can be difficult to distinguish from diffuse malignant mesothelioma (DMM) using traditional morphologic approaches. Standard panels of immunohistochemical markers are of limited benefit. Objective.-To investigate several antibodies to renal cell carcinoma-associated proteins for differentiating MRCC from DMM. Design.-One hundred DMMs and 20 MRCCs were evaluated for immunoexpression of erythropoietin. The same cases and an additional 45 DMMs were evaluated for CD10 and renal cell carcinoma marker (RCCMa) immunoreactivity. Results.- Erythropoietin was expressed in 100{\%} of DMMs and MRCCs. Staining for CD10 was observed in 54{\%} of DMMs and 100{\%} of MRCCs. RCCMa stained 26{\%} of DMMs and 55{\%} of MRCCs. Although erythropoietin staining was similarly strong and diffuse in both DMM and MRC, patterns of staining for RCCMa and CD10 differed between MRCC and DMM. Immunoreactivity was strong and diffuse for both RCCMa and CD10 in most MRCCs. Of CD10-positive DMMs, nearly half showed staining in less than 50{\%} of tumor cells and about one fourth of positive cases exhibited only weak to moderately intense staining. Only half of RCCMa-positive DMMs showed staining in more than 49{\%} of tumor cells and staining was only weak to moderately intense in most cases. Conclusions.-Given the overlap in the expression of renal cell carcinoma markers in MRCC and DMM, results with these markers must be interpreted cautiously and should be used in conjunction with mesothelium-associated markers. Differences in expression may potentially help distinguish MRCC from DMM inasmuch as strong and diffuse expression of RCCMa and CD10 supports a diagnosis of MRCC over DMM.",
author = "Butnor, {Kelly J.} and Nicholson, {Andrew G.} and Allred, {D. Craig} and Zander, {Dani S.} and Henderson, {Douglas W.} and Roberto Barrios and Haque, {Abida K.} and Allen, {Timothy C.} and Killen, {Deanna E.} and Cagle, {Philip T.}",
year = "2006",
month = "6",
language = "English (US)",
volume = "130",
pages = "823--827",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "6",

}

TY - JOUR

T1 - Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma

AU - Butnor, Kelly J.

AU - Nicholson, Andrew G.

AU - Allred, D. Craig

AU - Zander, Dani S.

AU - Henderson, Douglas W.

AU - Barrios, Roberto

AU - Haque, Abida K.

AU - Allen, Timothy C.

AU - Killen, Deanna E.

AU - Cagle, Philip T.

PY - 2006/6

Y1 - 2006/6

N2 - Context.-Metastatic renal cell carcinoma (MRCC) involving the thorax can be difficult to distinguish from diffuse malignant mesothelioma (DMM) using traditional morphologic approaches. Standard panels of immunohistochemical markers are of limited benefit. Objective.-To investigate several antibodies to renal cell carcinoma-associated proteins for differentiating MRCC from DMM. Design.-One hundred DMMs and 20 MRCCs were evaluated for immunoexpression of erythropoietin. The same cases and an additional 45 DMMs were evaluated for CD10 and renal cell carcinoma marker (RCCMa) immunoreactivity. Results.- Erythropoietin was expressed in 100% of DMMs and MRCCs. Staining for CD10 was observed in 54% of DMMs and 100% of MRCCs. RCCMa stained 26% of DMMs and 55% of MRCCs. Although erythropoietin staining was similarly strong and diffuse in both DMM and MRC, patterns of staining for RCCMa and CD10 differed between MRCC and DMM. Immunoreactivity was strong and diffuse for both RCCMa and CD10 in most MRCCs. Of CD10-positive DMMs, nearly half showed staining in less than 50% of tumor cells and about one fourth of positive cases exhibited only weak to moderately intense staining. Only half of RCCMa-positive DMMs showed staining in more than 49% of tumor cells and staining was only weak to moderately intense in most cases. Conclusions.-Given the overlap in the expression of renal cell carcinoma markers in MRCC and DMM, results with these markers must be interpreted cautiously and should be used in conjunction with mesothelium-associated markers. Differences in expression may potentially help distinguish MRCC from DMM inasmuch as strong and diffuse expression of RCCMa and CD10 supports a diagnosis of MRCC over DMM.

AB - Context.-Metastatic renal cell carcinoma (MRCC) involving the thorax can be difficult to distinguish from diffuse malignant mesothelioma (DMM) using traditional morphologic approaches. Standard panels of immunohistochemical markers are of limited benefit. Objective.-To investigate several antibodies to renal cell carcinoma-associated proteins for differentiating MRCC from DMM. Design.-One hundred DMMs and 20 MRCCs were evaluated for immunoexpression of erythropoietin. The same cases and an additional 45 DMMs were evaluated for CD10 and renal cell carcinoma marker (RCCMa) immunoreactivity. Results.- Erythropoietin was expressed in 100% of DMMs and MRCCs. Staining for CD10 was observed in 54% of DMMs and 100% of MRCCs. RCCMa stained 26% of DMMs and 55% of MRCCs. Although erythropoietin staining was similarly strong and diffuse in both DMM and MRC, patterns of staining for RCCMa and CD10 differed between MRCC and DMM. Immunoreactivity was strong and diffuse for both RCCMa and CD10 in most MRCCs. Of CD10-positive DMMs, nearly half showed staining in less than 50% of tumor cells and about one fourth of positive cases exhibited only weak to moderately intense staining. Only half of RCCMa-positive DMMs showed staining in more than 49% of tumor cells and staining was only weak to moderately intense in most cases. Conclusions.-Given the overlap in the expression of renal cell carcinoma markers in MRCC and DMM, results with these markers must be interpreted cautiously and should be used in conjunction with mesothelium-associated markers. Differences in expression may potentially help distinguish MRCC from DMM inasmuch as strong and diffuse expression of RCCMa and CD10 supports a diagnosis of MRCC over DMM.

UR - http://www.scopus.com/inward/record.url?scp=33745019181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745019181&partnerID=8YFLogxK

M3 - Article

VL - 130

SP - 823

EP - 827

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 6

ER -